pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), Immune checkpoint association versus platinum association, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.65, 0.96]< 10%1 study (1/-)99.1 %NAnot evaluable crucial-
progression or deaths (PFS) 0.71 [0.51, 1.00]< 168%2 studies (2/-)97.7 %some concernnot evaluable moderateimportant-
objective responses (ORR) 1.66 [0.97, 2.82]> 172%2 studies (2/-)96.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

STRAE (any grade) 2.15 [1.58, 2.92]< 10%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-
STRAE (grade 3-4) 2.04 [1.44, 2.88]< 10%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-
TRAE (any grade) 0.88 [0.46, 1.67]< 171%2 studies (2/-)65.4 %some concernnot evaluable moderatenon important-
TRAE (grade 3-4) 0.98 [0.76, 1.26]< 10%2 studies (2/-)56.6 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 0.99 [0.28, 3.45]< 10%1 study (1/-)50.7 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 3.25 [2.20, 4.78]< 10%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-
TRAE leading to discontinuation (grade 3-4) 4.01 [2.31, 6.97]< 115%2 studies (2/-)0.0 %some concernnot evaluable moderatenon important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 0.15 [0.07, 0.33]< 19%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
Asthenia TRAE (grade 3-4) 1.22 [0.44, 3.39]< 10%2 studies (2/-)35.4 %some concernnot evaluable moderatenon important-
Constipation TRAE (grade 3-4) 0.73 [0.06, 9.60]< 10%2 studies (2/-)59.2 %some concernnot evaluable moderatenon important-
Decreased appetite TRAE (grade 3-4) 0.70 [0.21, 2.26]< 10%2 studies (2/-)72.6 %some concernnot evaluable moderatenon important-
Diarrhoea TRAE (grade 3-4) 2.38 [0.72, 7.91]< 10%2 studies (2/-)7.8 %some concernnot evaluable moderatenon important-
Fatigue TRAE (grade 3-4) 0.96 [0.15, 6.03]< 156%2 studies (2/-)51.9 %some concernnot evaluable moderatenon important-
Hypothyroidism TRAE (grade 3-4) 1.18 [0.02, 59.79]< 10%1 study (1/-)46.8 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.51 [0.13, 2.03]< 120%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
Neutropenia TRAE (grade 3-4) 0.02 [0.00, 0.14]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
Pruritus TRAE (grade 3-4) 4.35 [0.48, 39.10]< 10%2 studies (2/-)9.6 %some concernnot evaluable moderatenon important-
Rash TRAE (grade 3-4) 11.73 [1.48, 92.76]< 10%2 studies (2/-)1.0 %some concernnot evaluable moderatenon important-
Vomiting TRAE (grade 3-4) 0.13 [0.03, 0.59]< 10%2 studies (2/-)99.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons